Clinical Trials Logo

Heavy Menstrual Bleeding clinical trials

View clinical trials related to Heavy Menstrual Bleeding.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05406960 Completed - Hysterectomy Clinical Trials

Therapeutic Effect of Herbal Infusion on Menometrorrhagia

HERBALTREAT
Start date: May 10, 2019
Phase: N/A
Study type: Interventional

This is an interventional, non-randomized, controlled, pilot study that explores a new approach to treat, Abnormal uterine bleeding-menometrorrhagia in women, being candidates for hysterectomy, based on tea infusion consumption of a mixture of two plants.

NCT ID: NCT05176496 Completed - Clinical trials for Heavy Menstrual Bleeding

A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment

Champion-HMB
Start date: November 30, 2021
Phase:
Study type: Observational

This is an observational study in which patient data from the past of females with heavy menstrual bleeding (HMB) is studied. • HMB describes menstrual periods with abnormally heavy or prolonged bleeding. Women concerned may not be able to maintain their usual activities during their period. Thus, HMB can reduce the quality of life and may lead to other medical problems. It is described that up to 30 of 100 women ask doctors for help concerning HMB during their fertile years. HMB is often not recognized and treated timely. In addition, there is little information about characteristics of women with HMB and real-world data on available treatments are missing. Despite the availability of non-invasive therapeutic options, for some women with severe HMB, surgical treatments (also called invasive) may be needed that can lead to infertility. - In this study researchers want to learn more about: - the percentage of women diagnosed with HMB - characteristics of these women like age at diagnosis or medical problems - treatment pathways of women with HMB in usual care Regarding treatment pathways, the researchers are especially interested in: - the percentage of women who use different therapeutic options over time - the percentage of women receiving invasive treatment for HMB after they received treatment as recommended by guidelines versus those not treated as recommended - To do this, researchers will collect information from five observational healthcare databases. Data will be from the year 2000 up to 2020. - Besides this data collection, no further tests or examinations are planned in this study. - In future, this information shall help to identify women with HMB and to learn what information may predict if invasive treatment will be needed later on.

NCT ID: NCT05007899 Completed - Clinical trials for Iron Deficiency Anemia

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

Start date: December 21, 2020
Phase: Phase 4
Study type: Interventional

Iron deficiency anemia affects over half of girls and young women with heavy periods and is the most common cause of anemia worldwide. Most girls with heavy periods who also have iron deficiency anemia are prescribed iron to take by mouth every day by their doctor. There are some studies showing that taking iron every other day may actually help the iron be absorbed into the bloodstream better. This study is trying to compare how taking iron every other day compares to taking iron daily for treatment of anemia. The goal of this clinical research study is to learn which of the two methods of care will be the best way for girls and young women with iron deficiency anemia to take iron supplementation.

NCT ID: NCT04425577 Completed - Contraception Clinical Trials

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

To determine if uterine cavity length on transabdominal pelvic ultrasound corresponds to uterine cavity length at time of IUD insertion. If transabdominal pelvic ultrasound is validated as a tool for measuring uterine cavity length, it can be used to guide physicians and subsequently patients in IUD insertion planning.

NCT ID: NCT03412890 Completed - Uterine Fibroid Clinical Trials

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Start date: October 19, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine the long-term efficacy and safety of relugolix 40 milligrams (mg) once daily co-administered with estradiol (E2) and norethindrone acetate (NETA) for 28 weeks on heavy menstrual bleeding associated with uterine fibroids in participants who previously completed a 24-week treatment period in one of the pivotal studies (MVT-601-3001 or MVT-601-3002).

NCT ID: NCT03368898 Completed - Clinical trials for Heavy Menstrual Bleeding

Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding

Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

Heavy menstrual bleeding or menorrhagia, is a common problem on women's lives and can burden both patients and health care systems. HMB is defined as cyclic heavy vaginal bleeding. Hormonal treatment of heavy menstrual bleeding (HMB) is also endorsed as the first line treatment in several international guidelines. The effects of these therapies on bleeding related quality of life are not well known. The aim of the present study is compare the effect of Estradiol Valerate/Dienogest (E2V/DNG), Levonorgestrel-Intrauterine Device (LNG-IUD) and oral micronized progesterone treatment on bleeding pattern, cycle control, menopausal symptoms and patient satisfaction of women with HMB.

NCT ID: NCT03317795 Completed - Uterine Fibroids Clinical Trials

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

Start date: November 14, 2017
Phase: Phase 4
Study type: Interventional

This is a randomized controlled trial (RCT) to assess the comparative effectiveness of Levonorgestrel Intrauterine System (LNG-IUS) to Tranexamic Acid (TA) for the treatment of heavy menstrual bleeding (HMB) in women with clinically-significant fibroids.

NCT ID: NCT03103087 Completed - Uterine Fibroid Clinical Trials

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Start date: June 14, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.

NCT ID: NCT03070951 Completed - Uterine Fibroids Clinical Trials

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

PRIMROSE 2
Start date: May 23, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

NCT ID: NCT03070899 Completed - Uterine Fibroids Clinical Trials

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

PRIMROSE 1
Start date: April 20, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.